Memphis Meats' lab-produced meatballs
There is a frustrating, 'jam tomorrow' aspect to all the talk around cell-based meat.
Perhaps it is the tantalising prospect of what might be achieved by the men and women in labs and what it might mean for the future of food that makes us keep asking the question of when we will see something more than a prototype of meat created without harming animals.
But the answer always seem to be that we are a couple of years away.
However, there do seem to be signs of progress. Specifically, costs associated with the process, previously sky high, do seem to be coming down.
It should be remembered that it was back in 2013 when Mosa Meat of the Netherlands created the world's first lab-grown burger at the eye-watering cost of EUR250,000 (US$295,594 at today's conversion rate).
Here we are seven years later and the products are still in the lab, seemingly a long way from supermarket shelves.
On the face of it, even for a layman, what is being done in those labs is relatively easy to understand.
Stem cells are taken from the muscle of an animal and added to a nutrient rich-solution called cell culture medium typically containing vitamins, sugars and proteins and left to multiply, or fatten, to create meat.
The environmental and animal-welfare benefits of this process succeeding has meant the nascent industry has enjoyed more media attention and investment dollars than many other areas of food product development, with the exception of plant-based meat alternatives, also known as alt-protein.
But, as was demonstrated seven years ago, the central issue facing the industry is no longer proof of concept. It can be done, even with trickier marbled cuts of meat such as steak, but can it be done at scale and at an affordable cost?
Some investors think so as they continue to back cell-based meat companies, enticed by the prospect of getting in early to a development offering so much promise on paper (and lab desk).
In January, Memphis Meats of the US secured US$161m in new funding with meat giant Tyson Foods once again among the consortium of investors.
The California-based company said in January it will use the funds to build a pilot production plant, expand its team and to "hit a major milestone of launching products into the market". However, it has not set an actual launch date.
David Kay, Memphis Meats' senior manager of communications and operations, tells just-food the company needs to develop additional infrastructure for production, with a pilot production facility a key element.
"The focus is on reducing the cost of production and increasing production scale. On both of these issues, we have made very significant progress since we were founded in 2015," Kay insists.
Mosa Meat is still pushing hard to get a product ready to scale up. It too has attracted investment from established food companies. Last month, Switzerland's Bell Food Group agreed to put EUR5m in the Dutch business.
Beckie Calder-Flynn, Mosa Meat's operations co-ordinator, says: "We are aiming for a first market introduction in the next few years. It is very difficult to commit to a particular time frame because there are still some scientific unknowns and factors outside our control, such as the regulatory process.
"The first introduction will likely be small-scale. Several years beyond that, we aim to be widely available in supermarkets and restaurants."
The thorny issue of the cost of producing at scale is never far from the surface.
Calder-Flynn says: "As with any technology, initial prices tend to be extremely high until the product is commercialised, production is made efficient, and then products are sold en masse.
"For us, we are currently working on up-scaling our equipment so that we can produce large quantities quickly and efficiently. This hasn't been done before and is complex.
"We estimate that commercialisation will bring the price of a burger down to EUR9.00, compared with the EUR250,000 it cost to make the first burger. The cost of a hamburger in the supermarket is around EUR1.00 and we expect that with further efficiency improvements we will be able to bring the price down to this level over the next decade.
"Ultimately, cultured meat should be cheaper than conventional meat given its production is more efficient. One cell sample can create up to 10,000kg of cultured meat. Our estimates suggest that at that rate we would only need 150 cows to satisfy the world's current meat demand.
"The bottleneck currently is production efficiency and speed. It takes about ten weeks to make a [cell-based] hamburger, which is obviously not suitable for commercial production, but this doesn't mean we can't produce at industrial scale in the future. Because cell growth is exponential, it takes ten weeks to produce one quarter pound hamburger, but only about 12 weeks to produce 100,000 hamburgers."
Mosa Meat claimed another breakthrough on cost recently when the company announced it had achieved an 80x reduction in the cost of the growth medium or nutrient mix for its lab-grown meat.
Part of that transition is to move away from FBS (Fetal Bovine Serum), the standard growth medium used by the cell-based meat industry.
California-based New Age Meats is another business at the forefront of the cell-based charge. At the end of July, it secured $2m from investors just six months after raising $2.7m in seed funding from a consortium of backers.
The company said the new seed extension funding will help it to continue to develop cell-based pork products.
Specifically, New Age Meats plans to further expand its food science department, implement more automation and robotics and continue to attempt to reduce the cost of its first lab-produced product, a pork sausage.
Like its rivals, New Age Meats is now working towards building a pilot facility, scaling product development and production and getting its first foods to market.
Derin Alemli, director of operations and finance at the business, admitted development has slowed down because of the coronavirus pandemic.
"Covid has set the process back a little bit. We've been figuring out how to get back into the lab. We are at about 80% capacity now so we are making progress," he says.
Alemli believes the company's focus on pork gives it a distinct advantage. "Pigs are highly researched animals and there's a huge market for it. Our first product is a pork sausage because it's easier to use pork than a marbled product such as steak."
On the issue of cost, Alemli is optimistic about the future of lab-created products.
"The costs have come down dramatically to the $800-$1,000 a pound range," he says. "The equipment is expensive but that is a one-off cost. It's the media to feed the cells [that ratchets up costs]. "If we are not at the $15-$20 a pound range in the future that's tough sledding."
Also working hard to create lab-based meat is the French company Gourmey. The company is attempting to create a cruelty-free version of foie gras.
The French delicacy, which directly translates as "fat liver," is traditionally made out of the liver of a duck or goose which has been force-fed or over-fed.
Company co-founder and CEO Nicolas Morin-Forest tells just-food Gourmey is building a "versatile platform" around duck stem cells.
"With our cells' ability to specialise into any cell type, including muscle cells, we will also bring more complex cuts of meat at some point once the scaffold-based cultured meat technologies will have matured," he says.
Morin-Forest will not commit to a specific launch date at this stage.
"We are currently working on a lab-scale foie gras prototype and will showcase it in the next months," he says.
Jack Bobo, the CEO of Futurity, a Washington DC-based "food foresight company that helps brands get ahead of trends," is someone who has kept a close eye on developments in the cell-based area.
In terms of timescale for scaling up production, he says: "Some of the companies have got a very aggressive timeline. Others say they are some way off from commercialisation. Certainly there is some hype around businesses trying to get exposure to the media and investors. Companies with adequate funding are a lot less aggressive in what they are saying."
Bobo, a former special adviser on food policy at the US Department of State, suggests there are "some real technical issues that companies are still tackling".
He also thinks they can be communicating their message better. "I have talked privately to some of these companies and I told them to drop the term 'clean meat'. If I was running a company I would not want to be sitting down with a journalist and talking about safety and ethics.
"It's highly offensive to livestock producers and ended up with 28 states trying to stop them using the term meat. It was a self-inflicted wound. If you are getting close to market you need to communicate to the market better."
Of course, getting that product to market depends on regulatory approval and success ultimately depends retailers and consumers wanting to eat cell-based meat.
On the regulatory front, the US seems further ahead than Europe.
In March 2019, the Department of Agriculture (USDA) and the Food and Drug Administration (FDA) announced they'd established a framework for regulating cell-based meat and poultry.
The USDA will oversee food processing, labelling and distribution and the FDA will conduct inspections and safety checks. Within the European Union, food produced from cell culture or tissue culture derived from animals falls within the scope of the EU Novel Foods Regulation. There are those in cell-based meat space that see the US as having made more progress on the regulation of the fledgling sectorthan the EU, with some entrepreneurs wanting more engagement from Brussels and asking whether its process needs to take the time it does. The EU's Novel Foods Regulation takes up to two years in practice to go through.
Getting retailers and consumers on board is, of course, then also key once any approval is handed down.
Kay at Memphis Meats is confident in this regard. He says: "Research suggests that roughly two-thirds of Americans would eat cell-based meat, and that the more consumers learn about our products, the more enthusiastic they become.
"We are anticipating a lot of excitement from consumers, and we've already heard from many major retailers and restaurant chains that are interested in our work."
Calder-Flynn at Mosa Meat agrees. "We receive emails every day from people all around the world who are excited and passionate about cultured meat and the vast majority of responses we get about our work are extremely positive. People are wanting to eat healthier, more sustainable, and animal-friendly meat and they strongly believe cultured meat can offer that."
Alemli at New Age Meats says the research it has seen and done shows there will be early adopters if it is at the right cost. "The rise in alt-protein is good for us."
He suggest ethics and a post-Covid focus on safety will also come into play. "The inside of a slaughterhouse is not an appetising place. Our environment is very sanitary. It is safer, better for the environment."
When considering when such products will see the light of day, could the answer be in hybrid products, linking animal cells and plant-based ingredients?
Alemli at New Age Meats says his company's sausage is "more of a hybrid product", adding: "I think hybrid is a way of getting consumers ready for it and getting to market at a quite reasonable cost."
A company developing hybrid products is none other than KFC, the global fast-food chicken giant.
In July, KFC announced it had joined forces with Russian firm 3D Bioprinting Solutions, which is developing additive bioprinting technology that uses a recipe of chicken cells and plant ingredients. The resulting product is likely to be trialled in Russia.
What the move demonstrates is even mainstream majors are starting to think about the concept of cell-based meat and how it can benefit their businesses.
And while they can be accused of many things, being slow to market isn't one of them.
Read the original:
A question of scale the growing pains of cell-based meat - just-food.com
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments